WHO guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection provide a public health approach for scaling up HIV care and treatment programmes and focus on simplified, harmonized and effective antiretroviral therapy (ART) regimens for use in resource-limited settings. In 2013, for the first time, WHO revised and combined guidelines for adults and adolescents, infants and children and pregnant women as well as other ARV-related guidance documents into one set of consolidated guidelines that addressed the use of ARV drugs for HIV treatment and prevention across all age groups and populations, based on the broad continuum of HIV care.
The cascade of HIV care, treatment and prevention services is increasingly integrated with antiretroviral drugs used for treating people living with HIV as well as for preventing HIV transmission. The WHO 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection provide recommendations on the use of ARV drugs for treatment and prevention and address other major aspects of HIV-related care. The guidelines also incorporate operational and service delivery guidance as well as guidance for programme managers on decision-making and programme planning.
The consolidated guidelines will be reviewed comprehensively every two years to incorporate the key clinical, operational and programmatic implications of new science and emerging best practices across populations, age groups and settings. To ensure a timely dissemination of technical, policy and programmatic information, WHO will issue supplements to the consolidated guidelines. The materials included in these supplements can provide new recommendations, describe best practices and provide important updates that supplement the most recent consolidated guidelines and are intended for clinical and technical leaders as well as for programme managers.